
Dameron Levest Jones
Examiner (ID: 18762, Phone: (571)272-0617 , Office: P/1618 )
| Most Active Art Unit | 1618 |
| Art Unit(s) | 1621, 1616, 3991, 1211, 1618, RD00, 1619, 1622, 1615 |
| Total Applications | 2574 |
| Issued Applications | 1523 |
| Pending Applications | 392 |
| Abandoned Applications | 685 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11728124
[patent_doc_number] => 20170189567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-06
[patent_title] => 'Cage-Like Bifunctional Chelators, Copper-64 Radiopharmaceuticals and PET Imaging Using the Same'
[patent_app_type] => utility
[patent_app_number] => 15/194425
[patent_app_country] => US
[patent_app_date] => 2016-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 16019
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15194425
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/194425 | Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same | Jun 26, 2016 | Issued |
Array
(
[id] => 12881047
[patent_doc_number] => 20180185524
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-05
[patent_title] => Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors
[patent_app_type] => utility
[patent_app_number] => 15/739234
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739234
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/739234 | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | Jun 23, 2016 | Abandoned |
Array
(
[id] => 16214001
[patent_doc_number] => 10729793
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-08-04
[patent_title] => Method for imaging arthritis
[patent_app_type] => utility
[patent_app_number] => 15/739220
[patent_app_country] => US
[patent_app_date] => 2016-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 17600
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 375
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739220
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/739220 | Method for imaging arthritis | Jun 22, 2016 | Issued |
Array
(
[id] => 13519685
[patent_doc_number] => 20180311385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-01
[patent_title] => NOVEL KININ-BASED THERANOSTIC PROBES FOR SOLID CANCERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/738671
[patent_app_country] => US
[patent_app_date] => 2016-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5712
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15738671
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/738671 | Kinin-based theranostic probes for solid cancers and uses thereof | Jun 22, 2016 | Issued |
Array
(
[id] => 13672849
[patent_doc_number] => 20160375158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-29
[patent_title] => COMPOUNDS FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME
[patent_app_type] => utility
[patent_app_number] => 15/186764
[patent_app_country] => US
[patent_app_date] => 2016-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15186764
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/186764 | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | Jun 19, 2016 | Issued |
Array
(
[id] => 13746757
[patent_doc_number] => 10166303
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-01-01
[patent_title] => Radio-imaging and radio-therapy of cancer using antibodies to HAAH
[patent_app_type] => utility
[patent_app_number] => 15/174239
[patent_app_country] => US
[patent_app_date] => 2016-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 2907
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174239
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/174239 | Radio-imaging and radio-therapy of cancer using antibodies to HAAH | Jun 5, 2016 | Issued |
Array
(
[id] => 13968363
[patent_doc_number] => 10213515
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-26
[patent_title] => Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same
[patent_app_type] => utility
[patent_app_number] => 15/169493
[patent_app_country] => US
[patent_app_date] => 2016-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 23
[patent_no_of_words] => 4877
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15169493
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/169493 | Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same | May 30, 2016 | Issued |
Array
(
[id] => 16429449
[patent_doc_number] => 10829516
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-10
[patent_title] => Peptidomimetics for imaging the ghrelin receptor
[patent_app_type] => utility
[patent_app_number] => 15/578105
[patent_app_country] => US
[patent_app_date] => 2016-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 74
[patent_no_of_words] => 12381
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15578105
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/578105 | Peptidomimetics for imaging the ghrelin receptor | May 26, 2016 | Issued |
Array
(
[id] => 12766411
[patent_doc_number] => 20180147305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => Risk Stratification
[patent_app_type] => utility
[patent_app_number] => 15/576272
[patent_app_country] => US
[patent_app_date] => 2016-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4131
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15576272
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/576272 | Risk Stratification | May 22, 2016 | Abandoned |
Array
(
[id] => 12766408
[patent_doc_number] => 20180147304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => Risk Stratification
[patent_app_type] => utility
[patent_app_number] => 15/576267
[patent_app_country] => US
[patent_app_date] => 2016-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15576267
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/576267 | Risk Stratification | May 22, 2016 | Abandoned |
Array
(
[id] => 12724549
[patent_doc_number] => 20180133350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-17
[patent_title] => SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING
[patent_app_type] => utility
[patent_app_number] => 15/576119
[patent_app_country] => US
[patent_app_date] => 2016-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13563
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15576119
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/576119 | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting | May 18, 2016 | Issued |
Array
(
[id] => 11289189
[patent_doc_number] => 20160339121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-24
[patent_title] => 'NOVEL ANIMAL MODELS FOR EVALUATING PHARMACEUTICAL COMPOUNDS'
[patent_app_type] => utility
[patent_app_number] => 15/151868
[patent_app_country] => US
[patent_app_date] => 2016-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6813
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15151868
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/151868 | Animal models for evaluating pharmaceutical compounds | May 10, 2016 | Issued |
Array
(
[id] => 16405482
[patent_doc_number] => 10814020
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-27
[patent_title] => Targeted protein contrast agents, methods of making, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/572863
[patent_app_country] => US
[patent_app_date] => 2016-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 80
[patent_figures_cnt] => 162
[patent_no_of_words] => 21149
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572863
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/572863 | Targeted protein contrast agents, methods of making, and uses thereof | May 10, 2016 | Issued |
Array
(
[id] => 13297697
[patent_doc_number] => 20180200385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-19
[patent_title] => ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES AS RADIO-SENSITIZERS AND MRI AND/OR X-RAY CONTRAST AGENTS
[patent_app_type] => utility
[patent_app_number] => 15/571763
[patent_app_country] => US
[patent_app_date] => 2016-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571763
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/571763 | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents | May 4, 2016 | Issued |
Array
(
[id] => 16381993
[patent_doc_number] => 10806804
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-20
[patent_title] => Compounds having RD targeting motifs and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 15/572087
[patent_app_country] => US
[patent_app_date] => 2016-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 34
[patent_no_of_words] => 18333
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572087
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/572087 | Compounds having RD targeting motifs and methods of use thereof | May 4, 2016 | Issued |
Array
(
[id] => 12702508
[patent_doc_number] => 20180126002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-10
[patent_title] => METHODS AND COMPOSITIONS FOR THERANOSTIC NANOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 15/570218
[patent_app_country] => US
[patent_app_date] => 2016-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -128
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15570218
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/570218 | Methods and compositions for theranostic nanoparticles | Apr 27, 2016 | Issued |
Array
(
[id] => 12676048
[patent_doc_number] => 20180117182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-03
[patent_title] => THROMBUS IMAGING APTAMERS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 15/570065
[patent_app_country] => US
[patent_app_date] => 2016-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15570065
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/570065 | Thrombus imaging aptamers and methods of using same | Apr 27, 2016 | Issued |
Array
(
[id] => 14697751
[patent_doc_number] => 10376598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-08-13
[patent_title] => Targeted therapeutics
[patent_app_type] => utility
[patent_app_number] => 15/138785
[patent_app_country] => US
[patent_app_date] => 2016-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 3
[patent_no_of_words] => 33993
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15138785
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/138785 | Targeted therapeutics | Apr 25, 2016 | Issued |
Array
(
[id] => 11023593
[patent_doc_number] => 20160220548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-04
[patent_title] => 'ANDROGEN RECEPTOR MODULATOR AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/094113
[patent_app_country] => US
[patent_app_date] => 2016-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44028
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094113
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/094113 | ANDROGEN RECEPTOR MODULATOR AND USES THEREOF | Apr 7, 2016 | Abandoned |
Array
(
[id] => 11009783
[patent_doc_number] => 20160206736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-07-21
[patent_title] => 'LIGANDS TO RADIATION-INDUCED MOLECULES'
[patent_app_type] => utility
[patent_app_number] => 15/094579
[patent_app_country] => US
[patent_app_date] => 2016-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24704
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094579
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/094579 | Ligands to radiation-induced molecules | Apr 7, 2016 | Issued |